 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Medicine > Pharmos Corporation
 |
Pharmos Corporation |
 |
 |
 |
PROFILE |
 |
Pharmos is focused on helping people see and think more clearly. The company develops products to treat ophthalmic, central nervous system (CNS), and neurological conditions. Its two approved products, Lotemax and Alrex, are marketed by Bausch & Lomb in the US. Lotemax is a topical steroid used to treat eye inflammations, and Alrex treats allergic conjunctivitis. Pharmos is also developing Dexanabinol, a neuroprotective compound that could prevent lasting damage from traumatic brain injury and stroke; the drug is currently in clinical trials. The firm is also developing Dexanabinol as a possible therapy for multiple sclerosis and other CNS and inflammatory conditions.
COMPETITION |
 |
Allergan, Inc. (AGN)
Novartis AG (NVS)
Schering AG (SHR)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 5.10
1-Yr. Sales Growth: 54.5%
Employees: 66
Revenue per employee: $77,272.73
KEY PEOPLE |
 |
Haim Aviv
CEO
Robert W. Cook
CFO
CONTACT INFO |
 |
99 Wood Ave. South, Ste. 301
Iselin, NJ 08830
US
Phone: 732-452-9556
Fax: 732-452-9557
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |